製品の概要

製品の詳細

  • 由来Recombinant
  • 由来Escherichia coli
  • アミノ酸配列
    • 生物種Human

特性

Our Abpromise guarantee covers the use of ab55754 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    SDS-PAGE

    Functional Studies

  • 精製度> 95 % SDS-PAGE.
    Purification assessed by SDS Page and HPLC.
  • 製品の状態Lyophilised
  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Preservative: None
    Constituents: 75mM Sodium chloride, 10mM Tris, pH 7.5
    Endotoxin level: < 0.1 ng per ug of Osteoprotegerin

  • 再構成The lyophilized Osteoprotegerin is soluble in most aqueous buffers. The lyophilized protein must be reconstituted in 5 mM Tris, pH 7.5 to a concentration of 0.1-1 mg/ml.

関連情報

  • 別名
    • MGC29565
    • OCIF
    • OPG
    • Osteoclastogenesis inhibitory factor
    • Osteoprotegerin
    • PDB5
    • TNF receptor superfamily member 11b
    • TNFRSF 11B
    • TNFRSF11B
    • TR 1
    • TR1
    • TR11B_HUMAN
    • Tumor necrosis factor receptor superfamily member 11B
    see all
  • 機能Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • 組織特異性Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • 関連疾患Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • 配列類似性Contains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • 翻訳後修飾N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • 細胞内局在Secreted.
  • Information by UniProt

Recombinant Human Osteoprotegerin protein (ab55754) 使用論文

This product has been referenced in:
  • Somja J  et al. Dendritic cells in Barrett's esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity? Am J Pathol 182:2168-79 (2013). Read more (PubMed: 23619476) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab55754.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"